Tivozanib for the treatment of renal cell carcinoma

References

• http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2018/; [ accessed 18th February 2018].
   Google Scholar
• Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression, Crit Rev Oncol Hematol. 2007;62:179–213.
   Google Scholar
• Haase VH. The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des. 2009;15:3895–3903.
   PubMed Web of Science ®Google Scholar
• Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 2004;93:297–302.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963–2970.
   PubMed Web of Science ®Google Scholar
• Puente Vázquez J, Alonso Gordoa T, Moreno J, et al. New challenges in kidney cancer management: integration of surgery and novel therapies. Curr Treat Options Oncol. 2015;16:337.
   PubMed Web of Science ®Google Scholar
• Santoni M, Conti A, Porta C, et al. Sunitinib, pazopanib or sorafenib for the treatment of patients with late-relapsing metastatic renal cell carcinoma. J Urol. 2015;193:41−7. .
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczack P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931−39.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35:591−97.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–1482.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007;356:2271–2281.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomised placebo-controlled phase III trial. Lancet. 2008;372:449−56.
   PubMed Web of Science ®Google Scholar
• Amantini C, Morelli MB, Santoni M, et al. Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience. 2015;2:395−409.
   PubMedGoogle Scholar
• Kim C, Baek SH, Um JY, et al. Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. BMC Nephrol. 2016;17:19.
   PubMed Web of Science ®Google Scholar
• Santoni M, Amantini C, Morelli MB, et al. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer. 2014;109:1040−50.
   Web of Science ®Google Scholar
• Hu W, Yuan Q, Liu XH, et al. Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma. Eur J Pharmacol. 2015;749:142−50.
   PubMed Web of Science ®Google Scholar
• Morelli MB, Amantini C, Santoni M, et al. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget. 2015;6:36245–36259.
   PubMedGoogle Scholar
• Hosokawa N, Hara T, Kaizuka T, et al. Nutrient–dependent mTORC1 association with the ULK1–atg13–FIP200 complex required for autophagy. Mol Biol Cell. 2009;20:1981–1991.
   PubMed Web of Science ®Google Scholar
• Nakamura K1, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006;66:9134–9142.
   PubMed Web of Science ®Google Scholar
• McTigue M, Murray BW, Chen JH, et al. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci U S A. 2012;109:18281–18289.
   PubMed Web of Science ®Google Scholar
• Eskens FA, De Jonge MJ, Bhargava P, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, −2, and −3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 2011;17:7156–7163.
   PubMed Web of Science ®Google Scholar
• Pavlakovic H, Becker J, Albuquerque R, et al. J. Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors. Ann N Y Acad Sci. 2010;1207(Suppl 1):E7–15.
   PubMedGoogle Scholar
• Momeny M, Moghaddaskho F, Gortany NK, et al. Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Sci Rep. 2017;7:44075.
   PubMed Web of Science ®Google Scholar
• Cotreau MM, Hale CL, Jacobson L, et al. Absorption, metabolism, and excretion of [(14) C]-tivozanib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in healthy male participants: a phase i, open-label, mass-balance study. Clin Pharmacol Drug Dev. 2012;1:102–109.
   PubMed Web of Science ®Google Scholar
• Fishman MN, Srinivas S, Hauke RJ, et al. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma. Eur J Cancer. 2013;49:2841–2850.
   PubMed Web of Science ®Google Scholar
• Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol. 2012;30:1678–1685.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31:3791–3799.
   PubMed Web of Science ®Google Scholar
• Molina AM, Hutson TE, Nosov D, et al. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. Eur J Cancer. 2018;94:87–94.
   PubMed Web of Science ®Google Scholar
• Escudier B, Barthelemy P, Ravaud A, et al. Tivozanib combined with nivolumab: phase Ib/II study in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36(suppl6S; abstr 618).
   Web of Science ®Google Scholar